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Abstract 
Background Previous studies evaluating the risk of cardiovascular diseases (CVD) in 
prostate cancer patients receiving androgen deprivation treatment (ADT) often did not 
distinguish different modalities of ADT. 
Methods We conducted a large, retrospective cohort study using the linked Surveillance, 
Epidemiology and End Results - Medicare database, including patients with primary 
localized prostate cancer diagnosed in 2007-2013 and followed through the end of 2014. 
Time dependent multivariable Cox proportional hazards models with death as the competing 
risk were used to evaluate the association between ADT (overall, and two subtypes: 
gonadotropin-releasing hormone [GnRH] agonists and oral antiandrogens) and incidence of 
CVD. 
Results  Among 20,239 prostate cancer patients, 32% received ADT. Receipt of ADT 
was associated with a 28% increase in the risk of CVD (hazard ratio [HR] = 1.28, 95% 
confidence interval [CI]: 1.14-1.67). The HRs for GnRH agonists and oral antiandrogens 
were 1.22 (95% CI: 1.15-1.30) and 1.11 (95% CI: 1.04-1.20), respectively.  
Conclusions In patients with primary, localized prostate cancer, ADT is associated with a 
significantly increased risk for CVD, and the magnitude of association appears higher for 
GnRH agonists than for oral antiandrogens.  
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 4 
Introduction 
 Prostate cancer is the most common type of cancer and the second leading cause of 
cancer mortality among men in the United States (US).1 An estimated 164,690 men will be 
diagnosed with prostate cancer in 2018 in the US2 and will face a decision with respect to 
therapy. Androgen deprivation therapy (ADT) is the mainstay treatment for prostate cancer - 
45% of prostate cancer patients are expected to receive some form of ADT in the course of 
their disease.3 Although ADT has been shown to reduce cancer-specific mortality, it is also 
associated with several side effects including reduced libido, erectile dysfunction, 
gynaecomastasia, depression, metabolic alterations, dementia and kidney failure.4-9 In 
addition, several studies have suggested that ADT, especially gonadotropin-releasing 
hormone (GnRH) agonists, may be associated with an increased risk of cardiovascular 
diseases (CVD).10-14 Consequently, the US Food and Drug Administration issued a safety 
warning regarding the increased CVD risk of GnRH agonists in 2010.15  
Previous studies on ADT and risk of CVD mainly investigated GnRH agonists. Oral 
antiandrogens, which has gained popularity in recent years.16,17 Few studies are available on 
different modalities of ADT and risk of CVD. A recent French study suggests that CVD risk 
may differ across ADT modalities, but the difference may not be meaningful. However, this 
study only followed patients up to 4 years18. In addition, studies which combined different 
modalities of ADT have contradictory findings regarding the association between ADT and 
the risk of CVD in prostate cancer patients.10,11,19,20 Punnen et al. observed no association 
between ADT and CVD specific mortality with patients matched by propensity scores,19 
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while Ziehr et al. reported that the association only existed in patients with preexisting 
CVD20. A Kaiser based study indicated a moderate association.10,11 However, insufficient 
data were available on different types of ADT. 
The purpose of this study is to fill the knowledge gaps identified above by assessing the 
potential association between the receipt of ADT (overall, as well as three subtypes: GnRH 
agonists, oral antiandrogens, and orchiectomy) and CVD risk in a large cohort of prostate 
cancer patients in the US.  
 
Method 
Data Source and Study Cohort 
We used the Surveillance, Epidemiology and End Results (SEER) - Medicare database, 
which links patient-level information on incident cancer diagnoses reported to the SEER 
registries with Medicare claims for inpatient, outpatient, and physician services21. The SEER 
registries are population-based and account for approximately 28% of the US population22. 
The Yale human investigation committee determined this study did not directly involve 
human subjects.  
We assembled a retrospective cohort of 32,234 patients newly diagnosed with first 
primary, localized prostate cancer (clinical stage T1 or T2) during 2007-2013 with the 
following eligibility criteria: 1) aged 66 to 99 years at diagnosis, 2) had known month of 
diagnosis, 3) were not reported from autopsy or death certificate only, and 4) had continuous 
Medicare fee-for-service coverage (Parts A and B) and was not enrolled in health 
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maintenance organizations from 12 months before diagnosis to the end of follow-up (i.e., the 
date a patient developed the first CVD event, the date a patient died, or December 31, 2014, 
whichever was earlier), and 5) continuously enrolled in Medicare Part D from diagnosis to 
the end of follow-up. To ensure all CVD events were newly developed after prostate cancer 
diagnosis, we further excluded patients who had Medicare claims indicative of CVD in the 12 
months before (n = 9889) or during (n = 194) the month of their prostate cancer diagnosis. 
Additionally, we excluded patients who received ADT before their prostate cancer diagnosis 
(n = 84), and patients who developed CVD between the diagnosis of prostate cancer and 
when they received ADT for the first time (n = 1034). The final study cohort consisted of 
20,239 patients (Figure 1).  
 
Ascertainment of ADT  
Using Medicare claims, we ascertained there different types of ADT: 1) GnRH 
analogists (Healthcare Common Procedure Coding System codes J9217, J9218, J9219, 
J1950, J9202, and relevant Medicare Part D drug national drug codes (NDCs) ; see Appendix 
Table 1); 2) orchiectomy (Common Procedure Terminology codes 54512, 54521, 54522, 
54530, 54535, 54690, and ICD-9 Procedure codes 62.3, 62.4, 62.41, and 62.42; see Appendix 
Table 2); and 3) oral antiandrogens ( Medicare Part D drug NDC codes; see Appendix Table 
1-2). The use of ADT overall and the three different types of ADT were evaluated 
dichotomously (ever vs. never).  
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Study Outcomes 
We identified CVD events after diagnosis based on the International Classification of 
Diseases, 9th edition [ICD-9] codes from Medicare claims (see Appendix 3). We required 
diagnosis codes must appear on one inpatient claim or at least two different claims that are 
more than 30 days apart. If a patient had multiple CVD events on the same date, the patient 
was assigned to a specific outcome group according to the sequence below: 1) acute 
myocardial infarction (AMI); 2) cardiac arrest; 3) stroke; 4) heart failure; 5) hypertensive 
heart disease with heart failure; 6) cardiomyopathy; 7) valvulopathy; 8) angina pectoris; and 
9) conduction disorder. CVD events were first evaluated as a single entity and then classified 
into three separate categories: 1) cardiac ischemia (including AMI, cardiac arrest and angina 
pectoris); 2) stroke; and 3) other CVD (including heart failure, cardiomyopathy, conduction 
disorder, hypertensive heart disease and valvulopathy).  
 
Other Variables of Interest 
To assess comorbidity, all inpatient, outpatient and carrier claims within 12 months 
before the date of prostate cancer diagnosis were identified to calculate a modified Elixhauser 
comorbidity score (0, 1, >1)23,24. In addition, we abstracted information on a number of 
sociodemographic and clinical characteristics, including age at prostate cancer diagnosis (65-
69, 70-74, 75-79, ≥80 years), race (white, non-white), marital status (married/unmarried), 
census division (northeast, midwest, south, west), residential area (urban/rural), percentage of 
residents living in poverty at the census tract level (<10%, ≥10%), clinical stage at diagnosis 
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(T1/T2), Gleason score (<7, 7, >7), level of prostate specific antigen (0.1-9.9, 10.0-20.0, 
≥20.1), influenza vaccination in the last 12 months (yes/no, as a proxy measure for healthcare 
utilization), and radiotherapy for prostate cancer (yes/no).   
 
Statistical Analysis 
Frequency distributions of demographic and socioeconomic characteristics were 
compared between prostate cancer patients who received ADT and those who did not receive 
ADT, using Pearson’s Chi-square tests. Death prior to the first CVD event was considered a 
competing risk event. All patients were followed till the development of their first CVD 
event, death, or December 31, 2014, whichever was earlier. The outcomes of interest were 
occurrences of the first CVD event. To account for patients transferring from one group to 
another group, Simon-Makuch method was used for a graphical representation of the 
probability of cardiovascular diseases according to the receipt of ADT, which was considered 
as a time-dependent variable.25 Competing risk Cox proportional hazards regression models 
using the Find and Gray method were used to provide estimates of the crude and adjusted 
hazard ratios (HRs) and corresponding 95% confidence intervals (CI) for the occurrence of 
CVD events.26 To account for immortal bias27, for a given patient, person-time before the 
receipt of the first ADT was considered unexposed to ADT and exposed thereafter. All 
variables described in the previous section were included in the models. In addition to 
analyzing ADT as one group, we also analyzed different types of ADT separately by 
including the three types of ADT in the same model simultaneously. As very few patients 
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received orchiectomy (either exclusively or in combination with GnRH agonists and/or oral 
antiandrogens, n = 89), we chose to adjust for orchiectomy in the model but did not present 
the results for orchiectomy separately. The proportional hazards assumption was tested by 
plotting Schoenfeld residuals. 
All tests were two-sided with p<0.05 indicating statistical significance. SAS version 9.4 
(SAS Inc. Cary, NC) was used to conduct the analyses.  
 
Results 
Baseline Characteristics 
A total of 20,239 men with primary localized prostate cancer were included in the cohort. 
Patients who received ADT were more likely to be older, black, unmarried, poorer, in T1 
stage and have received radiotherapy for prostate cancer (Table 1).   
Of these 20,239 patients, 6490 (32.1%) received ADT. Specifically, 3121 (15.4%), 588 
(2.9%), and 41 (0.2%) exclusively received GnRH agonists, oral antiandrogen, or 
orchiectomy, respectively; but a large number of prostate cancer patients (n = 2740, 13.5%) 
received combinations of two or three different types of ADT (Figure 2).  
After a mean follow-up of 4.1 (range:1-8) years, 26.9% (n=5463) patients developed 
CVD. As shown in Figure 3, 2995 (14.8%), 611(3.0%), and 1857 (9.2%) patients 
experienced cardiac ischemia, stroke and other CVD events, respectively.  
 As shown in Figure 4, patients received ADT were more likely to develop CVD 
(p=0.003). In the multivariate models, prostate cancer patients treated with ADT had a 
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significantly higher risk of developing CVD events compared with patients who did not 
receive ADT (HR = 1.28, 95% CI: 1.22 - 1.36; P < .0001) (Table 2). When further evaluated 
three groups of CVD events, receipt of ADT increased risk of cardiac ischemia, stroke, and 
other CVDs by 20% (95% CI: 1.10 - 1.32), 38% (95% CI: 1.14 - 1.67) and 39% (95% CI: 
1.25 - 1.54), respectively (Table 3). Among the nine specific types of CVD, significant 
associations were observed with angina pectoris, heart failure, hypertensive heart disease, and 
valvulopathy (Table 3).  
Based on a multivariable model that included GnRH agonists, oral antiandrogens, 
orchiectomy as binary variables simultaneously, we found that both GnRH agonists and oral 
antiandrogens were associated with a statistically significant, increased risk for CVD (Figure 
5), while orchiectomy did not appear to influence CVD risk. The magnitude of association 
with CVD as a single entity was higher for GnRH agonists (HR = 1.22; 95% CI: 1.15 - 1.30) 
than for oral antihydrogens (HR = 1.11, 95% CI: 1.01 - 1.20). In addition, analyses by the 
three groups of CVD suggested that receipt of GnRH agonists was significantly associated 
with increased risks of cardiac ischemia and other CVDs, but not stroke, while taking oral 
antiandrogens was associated with an increased risk of stroke, but not cardiac ischemia or 
other CVD (details not shown).  
 
Discussion 
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In this large population-based cohort of older prostate cancer patients, we found that 
ADT is significantly associated with an increased risk of CVD, and the magnitude of 
association appears higher for GnRH agonists than for oral antiandrogens.  
Most previous studies on ADT and risk of CVD mainly focused on GnRH agonists 
solely ADT.5,11,12,14,28-33 We were able to identify the use of GnRH agonists, oral 
antiandrogens, and orchiectomy from SEER-Medicare claims and accounted for a 
comprehensive set of sociodemographic and clinical characteristics of the patients as 
potential confounders. A previous study using SEER-Medicare database compared the 10-
year rates of CVD between ADT users and non-ADT users, however, they did not include 
oral antiandrogens as ADT12. 
Utilizing the SEER-Medicare database, we found significantly increased risks of most 
CVD events among prostate cancer patients who received ADT. This finding is consistent 
with several other studies that were based on large databases6,10,12-14,29. A recent prospective 
cohort study from Kaiser Permanente only found an increased risk of heart failure in men 
without preexisting CVD11. However, the Kaiser study included patients at all ages, thus 38% 
of patients in the Kaiser cohort were under the age of 65 years, while our cohort consists of 
Medicare beneficiaries who were at least 66 years in age.  
Our study evaluated the impact of ADT on CVD risk across modalities, with a focus on 
oral antiandrogens. Oral antiandrogens have been used more often in recent years but have 
not been systematically studied in terms of their impact on CVD risk16. Although oral 
antiandrogens are often used with other therapies, a recent randomized controlled trial 
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showed that there was no difference in all-cause mortality and prostate cancer related 
mortality between antiandrogen monotherapy and GnRH agonists17. In a French study, 
compared with GnRH agonists, combined androgen blockade was associated with an 
increased risk (HR= 1.6, 95% CI:1.3 - 2.0) and antiandrogen with a decreased risk (HR = 0.6, 
95% CI: 0.4 - 0.9) of ischaemic events18. We found that patients who received GnRH 
agonists had a higher risk of most CVD outcomes including cardiac ischemia, heart failure, 
cardiomyopathy and hypertensive heart disease, compared with patients who received oral 
antiandrogens. These are similar to the findings by Keating et al10. However, we also found 
that the use of oral antiandrogens was associated with a significantly increased risk of stroke, 
while GnRH agonists did not appear to influence stroke risk. Given the paucity of studies on 
oral antiandrogens and the lack of confirmation, our findings should be interpreted with 
caution, but they do underscore the importance of studying different subtypes of ADT. It may 
not be reasonable to treat ADT as a single entity when evaluating its impact on CVD risk.  
Our study has several strengths. First, the SEER-Medicare database enabled us to have a 
large sample size and a long follow-up of the patients, which is crucial for the ascertainment 
of CVD outcomes. Second, we take account a complete subtypes of ADT and include the 
information of oral antiandrogens, which have been used more often recently. Additionally, 
the time-dependent competing-risk Cox proportional hazards regression models allowed us to 
address immortal bias in the study. 
 Some limitations of our study should also be noted. With a retrospective cohort design, 
patients were not randomly assigned to treatment with ADT, and comparison of baseline 
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characteristics showed that sicker and older patients were more likely to receive ADT. 
Although we adjusted for a number of covariates in the model, residual confounding might 
still exist. Second, our study cohort only included older patients (age ≥ 66 years) who had 
continuous Medicare coverage and no pre-existing CVD, which likely limits the 
generalizability of our findings. In addition, multiple comparison problem may exist in this 
study as we have three major types of CVD outcomes and two subtypes of ADT. However, 
the p-values would be still significant after Bonferroni adjustment as almost all p-values for 
the three major types of CVD are smaller than 0.001. Finally, we were unable to analyze the 
association between orchiectomy and CVD risk due to the very small number of patients who 
underwent the surgical procedure.  
In conclusion, receipt of ADT is associated with an increased risk of CVD events in 
older men with localized prostate cancer. Compared with oral antiandrogens, GnRH agonists 
appears to confer a higher CVD risk. It is important for prostate cancer patients and their 
physicians to take the association between ADT and CVD risk into account when making 
treatment decisions.  
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Figure 1. Construction of Study Cohort Using the Linked SEER-Medicare Database. * 
CVD indicates cardiovascular diseases; PCa, prostate cancer; ADT, androgen deprivation 
therapy. 
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Table 1. Sociodemographic and Clinical Characteristics of Prostate Cancer Patients at 
Baseline by Receipt of Androgen Deprivation Therapy 
 
 Overall Androgen Deprivation Therapy P-value* 
 Never EVER 
Total 20239 13749 6490  
Age (years)     
  <70 6992 (34.6) 5440 (39.6) 1552 (23.9) <0.0001 
  70 – 74 7336 (36.3) 5174 (37.6) 2162 (33.3)  
  75 – 79 3805 (18.8) 2231 (16.2) 1574 (24.3)  
				≥80 2106 (10.4) 904 (6.6) 1202 (18.5)  
Race     
  White 16480 (81.4) 11458 (83.3) 5022 (77.4) <0.0001 
  Non-white 3759 (18.6) 2291 (16.7) 1468 (22.6)  
Marital status     
  Married 13320(65.8) 9312 (67.7) 4008 (61.8) <0.0001 
  Unmarried 3977 (19.7) 2548 (18.5) 1429 (22.0)  
Census Region     
  Northeast 3603 (17.8) 2277 (16.6) 1326 (20.4) <0.0001 
  Midwest 2672 (13.2) 1719 (12.5) 953 (14.7)  
  South 4898 (24.2) 3406 (24.8) 1492 (23.0)  
  West 9066 (44.8) 6347 (46.2) 2719 (41.9)  
Residential Area    
  Urban 16189 (80.0) 11651 (81.2) 5028 (77.5) <0.0001 
  Rural 4046 (20.0) 2584 (18.8) 1462 (22.5)  
% of Residents Living Under Census Tract  
  <10% 10659(52.7) 7461 (54.3) 3198 (49.3) <0.0001 
  ≥10% 9348 (46.2) 6125 (44.6) 3223 (49.7)  
Clinical stage at diagnosis   
  T1 12684 (62.7) 9097 (66.2) 3587 (55.3) <0.0001 
  T2 7555 (37.3) 4652 (33.8) 2903 (44.7)  
Gleason score     
  <7 7913 (39.1) 6678 (48.6) 1235 (19.0) <0.0001 
  7 7971 (39.4) 5308 (38.6) 2663 (41.0)  
  >7 3101 (15.3) 905 (6.6) 2196 (33.8)  
Prostate Specific Antigen   
  0.1-9.9 15890 (78.5) 11782 (85.7) 4108 (63.3) <0.0001 
  10.0-20.0 2869 (14.2) 1528 (11.1) 1341 (20.7)  
  ≥20.1 1480 (7.3) 439 (3.2) 1041 (16.2)  
Elixhauser Score   
  0 13418 (63.8) 8968 (65.2) 3937 (60.0) <0.0001 
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  1 5032 (24.9) 3312 (24.1) 1720 (26.5)  
  ≥2 2343 (11.6) 1469 (10.7) 874 (13.5)  
Influenza vaccine before diagnosis   
  Yes 9816 (48.5) 6641 (48.3) 3175 (48.9) 0.41 
  No 10423 (51.5) 7108 (51.7) 3315 (51.1)  
Radiotherapy     
  Yes 10801 (53.4) 5971 (43.4) 4830 (74.4) <0.0001 
  No 9438 (46.6) 7778 (56.6) 1660 (25.6)  
 *P-values were calculated using Pearson’s Chi-square test 
Column totals may not equal to the total due to missing values. 
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Figure 2. Types of Androgen Deprivation Therapy Received by Prostate Cancer 
Patients (n = 20,239) 
* GnRH: gonadotropin-releasing hormone agonists; Oral AA: oral antiandrogens; ADT: 
androgen deprivation treatment 
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Figure 3. Types of Cardiovascular Diseases Occurred in Prostate Cancer Patients (n = 
20,239) 
 
* CVD: cardiovascular diseases 
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Figure 4. Probability of Cardiovascular Diseases by Androgen Deprivation Therapy 
according to the Simon-Makuch method25 
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Table 2. Sociodemographic and Clinical Characteristics, Androgen Deprivation 
Therapy, and Risk of Cardiovascular Diseases in Prostate Cancer Patients* 
  
Non-ADT 
(N=13749) 
ADT 
(N=6490) 
Hazard 
Ratio 
95% Confidence 
Interval 
P-value 
ADT   1.28 1.22 - 1.36 <.0001 
Age (years)           
  <70 5440 (39.6) 1552 (23.9) 1.00     
  70 – 74 5174 (37.6) 2162 (33.3) 1.16 1.10 - 1.23 <.0001 
  75 – 79 2231 (16.2) 1574 (24.3) 1.36 1.27 - 1.45 <.0001 
  ≥80 904 (6.6) 1202 (18.5) 1.63 1.51 - 1.76 <.0001 
Race           
  White 11458 (83.3) 5022 (77.4) 1.00     
  Non-white 2291 (16.7) 1468 (22.6) 1.09 1.03 - 1.16 0.003 
Marital status         
  Married 9312 (67.7) 4008 (61.8) 1.00     
  Unmarried 2548 (18.5) 1429 (22.0) 1.06 1.00 - 1.12 0.047 
  Missing 1889 (13.7) 1053 (16.2) 0.99 0.93 - 1.06 0.874 
Census Region         
  Northeast 2277 (16.6) 1326 (20.4) 1.00     
  Midwest 1719 (12.5) 953 (14.7) 1.02 0.94 - 1.11 0.652 
  South 3406 (24.8) 1492 (23.0) 1.02 0.95 - 1.09 0.647 
  West 6347 (46.2) 2719 (41.9) 0.89 0.83 - 0.94 <.0001 
Residential Area         
  Urban 11651 (81.2) 5028 (77.5) 1.00     
  Rural 2584 (18.8) 1462 (22.5) 0.90 0.85 - 0.96 0.001 
% of Residents Living Under Census Tract       
  <10% 7461 (54.3) 3198 (49.3) 1.00     
  ≥10% 6125 (44.6) 3223 (49.7) 0.97 0.92 - 1.02 0.187 
Gleason score         
  <7 6678 (48.6) 1235 (19.0) 1.00     
  7 5308 (38.6) 2663 (41.0) 1.01 0.96 - 1.07 0.616 
  >7 905 (6.6) 2196 (33.8) 0.94 0.87 - 1.01 0.097 
Prostate-specific antigen          
  0.1-9.9 11782 (85.7) 4108 (63.3) 1.00     
  10.0-20.0 1528 (11.1) 1341 (20.7) 0.95 0.89 - 1.01 0.100 
  ≥20.1+ 439 (3.2) 1041 (16.2) 0.80 0.73 - 0.88 <.0001 
Elixhauser Score         
  0 8968 (65.2) 3937 (60.0) 1.00     
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Adjusted hazard ratios and 95% confidence intervals were derived from a multivariate, 
competing-risk Cox proportional hazards regression model. All variables listed were 
mutually adjust for each other. 
 
  
  1 3312 (24.1) 1720 (26.5) 1.28 1.22 - 1.35 <.0001 
  2 1469 (10.7) 874 (13.5) 1.58 1.48 - 1.69 <.0001 
Radiotherapy          
  No 7778 (56.6) 1660 (25.6) 1.00     
  Yes 5971 (43.4) 4830 (74.4) 0.94 0.89 - 0.98 0.008 
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Table 3. Androgen Deprivation Therapy for Prostate Cancer and Risk of 
Cardiovascular Diseases 
 
 N 
% of patients 
who have the 
event 
Adjusted HR 
(95% CI)* 
P-value 
Overall 5463 26.9 1.28 (1.22- 1.36) <0.001 
Cardiac Ischemia 2995 14.8 1.20 (1.10- 1.32) <0.001 
  AMI 314 1.55 1.00 (0.76- 1.31) 1.00 
  Angina Pectoris 2646 13.07 1.22 (1.11- 1.35) <0.001 
  Cardiac arrest 35 0.17 1.88 (0.97- 3.63) 0.06 
      
Stroke 611 3.02 1.38 (1.14- 1.67) <0.001 
      
Other heart diseases 1857 9.18 1.39 (1.25- 1.54) <0.001 
  Heart failure 672 3.32 1.59 (1.34- 1.90) <0.001 
  Cardiomyopathy 114 0.56 1.34 (0.89- 2.02) 0.16 
  Conduction disorder 18 0.09 1.06 (0.39- 2.91) 0.90 
  Hypertensive heart disease 36 0.18 3.04 (1.24- 7.49) 0.02 
  Valvulopathy 1017 5.02 1.22 (1.05- 1.41) 0.01 
 
*Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were derived from a single 
multivariable, competing-risk Cox proportional hazards regression model that adjusted for 
the following covariates: age at prostate cancer diagnosis (65-69, 70-74, 75-79, ≥80 years), 
race (white, non-white), marital status (married/unmarried), census division (northeast, 
midwest, south, west), percentage of residents living in poverty at the census tract level 
(<10%, ≥10%), Elixhauser score (0, 1, >1) and radiotherapy for prostate cancer (yes/no). 
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Figure 5. Adjusted Hazard Ratios and 95% Confidence Intervals for Risk of CVD 
Events in Prostate Cancer Patients Who Received GnRH Agonists or Oral 
Antiandrogens* 
 
 
 
*Competing-risk Cox proportional hazards model were adjusted for the following covariates: 
age at prostate cancer diagnosis (65-69, 70-74, 75-79, ≥80 years), race (white, non-white), 
marital status (married/unmarried), census division (northeast, midwest, south, west), 
percentage of residents living in poverty at the census tract level (<10%, ≥10%), Elixhauser 
score (0, 1, >1), radiotherapy for prostate cancer (yes/no) and orchiectomy(ever/never). 
Abbreviations: AA: antiandrogens; ADT: androgen deprivation therapy; CVD: 
cardiovascular disease; CI: cardiac ischemia; GnRH: gonadotropin-releasing hormone 
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Appendix 
 
Appendix 1. Codes Used to Identify Androgen Deprivation Therapy (Healthcare 
Common Procedure Coding System [HCPCS], Current Procedural Terminology [CPT], 
International Classification of Disease, Ninth Version [ICD-9]) 
 
Diagnosis or 
procedure  
HCPC
S  CPT  
ICD-9 
procedure   Comments  
GnRH  
(Leuprolide injection) 
J9217   
Leuprolide acetate (for depot 
suspension), 7. 5 mg 
J9218   Leuprolide acetate, per 1 mg 
J9219   Leuprolide acetate implant, 65 mg 
J1950   
Injection, leuprolide acetate (for 
depot suspension), per 3. 75 mg 
GnRH  
(Goserelin injection) J9202   
Goserelin acetate implant, per 3. 6 
mg 
Orchiectomy 
 54512  Excise lesion testis 
 54520  Removal of testis 
 54522  Orchiectomy partial 
 54530  Removal of testis 
 54535  Extensive testis surgery 
 54690  Laparoscopy orchiectomy 
  62.3 Unilateral orchiectomy 
  62.4 Bilateral Orchiectomy 
  62.41 
Removal of both testes at same 
operative episode 
  62.42 
Removal of both testes at same 
operative episode 
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Appendix 2. Drugs Identified for Androgen Deprivation Therapy Using Medicare Part 
D Claims 
 
Type GNN(Generic Name) BRN (Brand Name) 
GnRH agonists 
Buserelin Suprecur 
Buserelin Suprefact injectable 
Goserelin Zoladex 
Leuprolide Acetate Lupron Depot 
Leuprolide Acetate Prostap SR 
Leuprolide Acetate Enantone 
Leuprolide Acetate Lucrin Depot 
Leuprolide Acetate Trenantone-Gyn 
Leuprolide Lupron Depot 
Leuprolide Prostap SR 
Leuprolide Enantone 
Leuprolide Lucrin Depot 
Leuprolide Trenantone-Gyn 
Leuprorelin Lupron Depot 
Leuprorelin Prostap SR 
Leuprorelin Enantone 
Leuprorelin Lucrin Depot 
Leuprorelin Trenantone-Gyn 
Naferelin Synarel 
Naferelin Synarella 
Triptorelin Decapeptyl SR 
Triptorelin Gonapeptyl 
Triptorelin Supprelin LA 
Triptorelin Trelstar Depot 
Degarelix Firmagon 
Abarelix Plenaxis 
Histrelin Vantas 
Oral antiandrogens 
Flutamide Eulexin 
Bicalutamide Casodex 
Nilutamide Nilandron 
Enzalutamide Xtandi 
Abiraterone Zytiga 
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Appendix 3. International Classification of Disease, Ninth Version [ICD-9] Codes Used 
to Identify Cardiovascular Diseases from Medicare Part B Claims 
CVD diagnoses ICD9 Comment 
Acute Myocardial Infarction 410 Acute myocardial infarction 
Cardiac Arrest 427.5 Cardiac arrest 
Stroke 
430 Subarachnoid hemorrhage 
431 Intracerebral hemorrhage 
432 Other and unspecified intracranial hemorrhage 
434 Occlusion of cerebral arteries 
436 Acute, but ill-defined, cerebrovascular disease 
Heart Failure (HF) 428 Heart failure 
Hypertensive Heart Disease 
with HF 
402.01 
Malignant hypertensive heart disease with 
heart failure 
402.11 
Benign hypertensive heart disease with heart 
failure 
402.91 
Unspecified hypertensive heart disease with 
heart failure 
Cardiomyopathy 
425.1 Hypertrophic cardiomyopathy 
425.3 Endocardial fibroelastosis 
425.4 Endocardial fibroelastosis 
425.8 
Cardiomyopathy in other diseases classified 
elsewhere 
425.9 Secondary cardiomyopathy, unspecified 
Arrhythmias 427 Cardiac dysrhythmias 
Valvulopathy 424 Other diseases of endocardium 
Angina Pectoris 
411 
Other acute and subacute forms of ischemic 
heart disease 
413 Angina pectoris 
414 Other forms of chronic ischemic heart disease 
Conduction Disorder 426.9 Conduction disorder, unspecified 
 
 
 
 
 
 
 
 
 
 
